Cochlear gene therapy
- PMID: 22157110
- PMCID: PMC3755754
- DOI: 10.1097/WCO.0b013e32834f038c
Cochlear gene therapy
Abstract
Purpose of review: This review highlights recent advances in cochlear gene therapy over the past several years. Cochlear gene therapy has undergone tremendous advances over the past decade. Beginning with some groundbreaking work in 2005 documenting hair cell regeneration using virally mediated delivery of the mouse atonal 1 gene, gene therapy is now being explored as a possible treatment for a variety of causes of hearing loss.
Recent findings: Recent advances in cochlear gene therapy include improved methods of gene delivery with a better delineation of viral vectors that are suitable for this purpose, additional improvements in hair cell regeneration, and directed research toward autoimmune hearing loss, ototoxicity, spiral ganglion survival, and genetic forms of hearing loss.
Summary: If successful, cochlear gene therapy will dramatically alter our ability to treat a variety of forms of acquired and genetic hearing loss.
References
-
- Smith RJ, Bale JF, Jr., White KR. Sensorineural hearing loss in children. Lancet. 2005 Mar 5-11;365:879. - PubMed
-
- Di Domenico M, et al. Towards gene therapy for deafness. J Cell Physiol. 2010 Dec 29; - PubMed
-
- Petersen MB, Willems PJ. Non-syndromic, autosomal-recessive deafness. Clin Genet. 2006 May;69:371. - PubMed
-
- Dror AA, Avraham KB. Hearing impairment: a panoply of genes and functions. Neuron. 2010 Oct 21;68:293. - PubMed
-
- Kral A, O’Donoghue GM. Profound deafness in childhood. The New England journal of medicine. 2010 Oct 7;363:1438. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous